Follicular Lymphoma, Relapsed/Refractory Follicular Lymphoma
Conditions
Keywords
follicular lymphoma, relapsed/refractory disease, survival
Brief summary
The optimal treatment strategy in patients with early progressive disease is not well known. In recent years, novel insights into the biology of Follicular Lymphoma (FL), and especially the role of the microenvironment, have resulted in the development of multiple novel treatment modalities. These new agents may ultimately improve the outlook for patients with FL with an unfavorable course, but for the development of the optimal therapeutic strategy, knowledge on the clinical and biological determinants of early refractory FL is needed.
Detailed description
Patients with histologically confirmed follicular lymphoma are registered in the study at the time of the first event after first line treatment. An event is defined as refractory/relapsed disease documented by biopsy, imaging, or clinical evaluation. Registration is based on the locally established histological diagnosis, with exclusion of cases diagnosed on fine needle aspiration cytology, while tru-cut core-needle biopsies are permitted in the study. Registration will be done on-line on a key restricted accessible web-database: the Investigator must complete the on-line registration form after obtaining informed consent dated and signed by the patient. Investigators are requested to register consecutive cases diagnosed at each participating Institution (all patients satisfying Inclusion criteria without any further selection). A patient number (Patient ID) will be assigned strictly sequentially in ascending order as patient's eligibility is verified. In case a patient's eligibility is not confirmed and the patient is withdrawn from the study, the patient number will not be reused. The assigned number will be used as the identification code for the subject. Every registered case has to undergo histopathology review by a panel of experts. The reference pathologist will collect and review the pathology material sent by the participating centers, without knowledge of the clinical outcome of the patient. Both material obtained at diagnosis, and at relapse will be reviewed. Classification will be performed according to the World Health Organization recently published.
Interventions
None listed
Sponsors
Associazione Angela Serra per la ricerca sul cancro
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
European Hematology Association - Lymphoma Group
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with initial diagnosis of follicular lymphoma, refractory/relapsed/transformed after first line therapy; * All stages at the time of relapse; * Histological grade 1-3a at the time of initial diagnosis; * Age over 18 years; * Availability of clinical data, including baseline information, comorbidities, data on disease localization, laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating as requested * Diagnostic material available for review; * Written informed consent.
Exclusion criteria
• Age \< 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Progression of disease within 24 months from start of second line treatment (second POD24) | 24 months | Second POD24 is defined as the rate of progression of disease at 24 months after the second line treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | 3 and 5 years | Overall Survival is measured from the date of diagnosis until death from any cause. |
| Progression-free survival after second line therapy (second PFS) | 3 and 5 years | Second PFS is measured from the date of study entry until the date of disease progression or death from any cause. |
| Complete response rate at 30 months (CR30) from start of second line treatment (second CR30) | 30 months | Second CR30 is defined as the rate of complete remissions at 30 months from start of second line treatment. |
Countries
Croatia, Italy, Netherlands, Portugal, Spain, Ukraine
Contacts
Primary ContactSanne Tonino, MD
Backup ContactIrene Dogliotti, MD
Outcome results
None listed